Vitalgenics Inc, a clinical stage biopharmaceutical company specializing in pancreatic cancer, has unraveled the etiology of pancreatic ductal adenocarcinoma (PDAC) with their FDA repurposed immunotherapy drug called Excindogen. 95% of all pancreatic cancers are PDAC with a 7%- 9% survival rate after 5 years.
PDAC consist of 40 continuous biological sequences within the pancreatic duct that upsets pancreatic duct homeostasis, initiated by bile toxicity, which starts a chain of events that make up tumor formation, tumor growth and metastasis. Some of the major sequences within the duct consist of neurotransmitters, cell signaling, ion channels, efflux pumps, hypoxia, DNA damage, several gene expressions such as KRAS, metabolic imbalances, manufacture of dense stroma and most important T- Cell exhaustion where the T- cells cannot attack and kill off the tumor. CEO Charles Owen states “it is like a faucet on full that cannot be turned off.” To turn off the faucet, homeostasis of the pancreatic duct needs to be stabilized so the T-cells can be reactivated to attack and kill off the tumor. The tumor consists of three major cells- The acinar “cancer” cell, the hijacked macrophage cell and the inflammatory cell, causing a “vicious cycle” where they feed on each other and where they proliferate that cannot be resolved with current chemotherapy.
In preclinical studies, immunotherapy drug Excindogen, has proven to inhibit the major sequences listed above, having the capability of “turning off the faucet” and returning homeostasis back to normal so that T-cells can reactivate, attack and kill tumors, while programming adaptive immunity so the tumor has a less of a chance of returning. Preclinical studies have also shown that Excindogen is non- toxic with no major side effects which will make a huge impact with patients. Toxicity and side effects are the main reason patients are non-compliant with current chemotherapy drugs. Excindogen has received orphan drug designation.
Vitalgenics Inc, is seeking capital to enter a phase 1/2 clinical trial and FDA submissions for advanced stage pancreatic cancer. For more information on the biological sequences or Excindogen please contact:
Charles Owen, CEO